These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 34625283)
1. The Health Care Resource Utilization and Costs Among Patients With Type 2 Diabetes and Either Cardiovascular Disease or Cardiovascular Risk Factors An Analysis of a US Health Insurance Database. Meyers J; Hoog M; Mody R; Yu M; Davis K Clin Ther; 2021 Nov; 43(11):1827-1842. PubMed ID: 34625283 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study. Olufade T; Jiang L; Israni R; Huang J; Gosmanov AR Diabetes Obes Metab; 2021 Dec; 23(12):2741-2751. PubMed ID: 34405521 [TBL] [Abstract][Full Text] [Related]
3. Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis. Kangethe A; Lawrence DF; Touya M; Chrones L; Polson M; Evangelatos T BMC Health Serv Res; 2021 Aug; 21(1):778. PubMed ID: 34362353 [TBL] [Abstract][Full Text] [Related]
4. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations. Annavarapu S; Ghosh S; Li Y; Moretz C; Shetty S; Prewitt T Am J Manag Care; 2020 Jun; 26(6):e166-e171. PubMed ID: 32549065 [TBL] [Abstract][Full Text] [Related]
5. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease. King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459 [TBL] [Abstract][Full Text] [Related]
6. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both. Nguyen C; Luthra R; Kuti E; Willey VJ Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310 [TBL] [Abstract][Full Text] [Related]
7. Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel. Melzer Cohen C; Hallén N; Chodick G; Bourvine L; Waner T; Karasik A Value Health Reg Issues; 2020 Sep; 22():83-92. PubMed ID: 32798839 [TBL] [Abstract][Full Text] [Related]
8. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Mody R; Meyers J; Yu M; Davis K; Levine JA Curr Med Res Opin; 2022 Nov; 38(11):1785-1795. PubMed ID: 35758147 [TBL] [Abstract][Full Text] [Related]
9. Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. Coutinho AD; Raju AD; Wang W; Stafkey-Mailey D; Shetty S; Sander SD Curr Med Res Opin; 2018 Jun; 34(6):1005-1012. PubMed ID: 29378486 [TBL] [Abstract][Full Text] [Related]
10. Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: "INSIST" study. Mohammedi K; Fauchier L; Quignot N; Khachatryan A; Banon T; Kapnang R; Kikuchi K; Ren H; Massien C; Vigié L; Larsen S; Sibon I Cardiovasc Diabetol; 2024 May; 23(1):183. PubMed ID: 38812009 [TBL] [Abstract][Full Text] [Related]
11. Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study. Shore AC; Colhoun HM; Natali A; Palombo C; Khan F; Östling G; Aizawa K; Kennbäck C; Casanova F; Persson M; Gooding K; Gates PE; Looker H; Dove F; Belch J; Pinnola S; Venturi E; Kozakova M; Goncalves I; Kravic J; Björkbacka H; Nilsson J; Diabetes Care; 2018 Oct; 41(10):2212-2219. PubMed ID: 30061319 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular event costs in patients with Type 2 diabetes mellitus. Johnston SS; Sheehan JJ; Shah M; Cappell K; Princic N; Smith D; Kalsekar I J Med Econ; 2015; 18(12):1032-40. PubMed ID: 26189723 [TBL] [Abstract][Full Text] [Related]
13. Association of Ideal Cardiovascular Health and Long-term Healthcare Costs. Willis BL; DeFina LF; Bachmann JM; Franzini L; Shay CM; Gao A; Leonard D; Berry JD Am J Prev Med; 2015 Nov; 49(5):678-685. PubMed ID: 26141912 [TBL] [Abstract][Full Text] [Related]
14. Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. Punekar RS; Fox KM; Richhariya A; Fisher MD; Cziraky M; Gandra SR; Toth PP Clin Cardiol; 2015 Aug; 38(8):483-91. PubMed ID: 26100722 [TBL] [Abstract][Full Text] [Related]
15. Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin. Parker ED; Wittbrodt ET; McPheeters JT; Frias JP Diabetes Obes Metab; 2019 Feb; 21(2):227-233. PubMed ID: 30101553 [TBL] [Abstract][Full Text] [Related]
16. High prevalence of cardiovascular disease and risk factors among type 2 diabetes patients followed in a hospital setting in Portugal: The PICT2RE observational study. Cardoso H; Tavares Bello C; Andrade L; Sobral do Rosário F; Louro J; Nogueira C; Rodrigues E; Vieira NB; Carqueja T; Rev Port Cardiol; 2023 Apr; 42(4):319-330. PubMed ID: 36634764 [TBL] [Abstract][Full Text] [Related]
17. Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study. Bernfort L; Husberg M; Wiréhn AB; Rosenqvist U; Gustavsson S; Karlsdotter K; Levin LÅ Diabetes Ther; 2020 Jul; 11(7):1537-1549. PubMed ID: 32468515 [TBL] [Abstract][Full Text] [Related]
18. Burden of influenza in patients with cardiovascular disease who receive antiviral treatment for influenza. Corral M; Castro RC; To TM; Arndorfer S; Wang S; Stephens J J Med Econ; 2022; 25(1):1061-1067. PubMed ID: 35943115 [TBL] [Abstract][Full Text] [Related]
19. Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database. Al-Jedai AH; Almudaiheem HY; Alissa DA; Al-Enazy HS; Korayem GB; Alghamdi A; Alghamdi S PLoS One; 2022; 17(10):e0273836. PubMed ID: 36264903 [TBL] [Abstract][Full Text] [Related]
20. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis. Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]